Daily Ards Research Analysis
Across ARDS-related research today: a PRISMA-compliant meta-analysis finds no clinical benefit of imatinib for COVID-19, a neonatal cohort identifies KLF2, YKL-40, and vitamin A as prognostic biomarkers in NRDS, and a small retrospective study supports lung ultrasound scoring to assess ventilation status in moderate-to-severe ARDS.
Summary
Across ARDS-related research today: a PRISMA-compliant meta-analysis finds no clinical benefit of imatinib for COVID-19, a neonatal cohort identifies KLF2, YKL-40, and vitamin A as prognostic biomarkers in NRDS, and a small retrospective study supports lung ultrasound scoring to assess ventilation status in moderate-to-severe ARDS.
Research Themes
- Therapeutic efficacy in COVID-19-associated ARDS
- Biomarker-driven risk stratification in neonatal respiratory distress
- Point-of-care imaging for ARDS ventilation assessment
Selected Articles
1. Efficacy and safety of imatinib in patients with COVID-19: a systematic review and meta-analysis.
Across four RCTs (n=717), imatinib did not reduce 28-day mortality, oxygen supplementation duration, ventilator-free days, or lengths of stay versus placebo in COVID-19. Adverse event rates were similar. The authors suggest future subgroup analyses by COVID-19-associated ARDS phenotypes or IL-6 receptor inhibitor co-therapy.
Impact: This PRISMA-compliant meta-analysis synthesizes randomized evidence to clarify that imatinib offers no measurable clinical benefit in COVID-19, guiding resource allocation and trial design.
Clinical Implications: Avoid routine use of imatinib for COVID-19 outside trials. Consider targeting specific inflammatory phenotypes or IL-6 inhibitor co-therapy only within well-designed studies.
Key Findings
- 28-day mortality was not reduced with imatinib vs placebo (RR 0.79, 95% CI 0.51–1.21; p=0.28).
- No significant differences in oxygen supplementation duration (MD −0.13 days; p=0.92) or ventilator-free days (MD 4.71; p=0.43).
- Hospital and ICU length of stay and rates of any or serious adverse events were similar between groups.
Methodological Strengths
- PRISMA-guided systematic search and meta-analysis
- Inclusion limited to randomized controlled trials
Limitations
- Only four RCTs with moderate total sample size
- Potential heterogeneity in populations and concomitant therapies; limited power for subgroup effects
Future Directions: Prospective, phenotype-enriched trials and individual patient data meta-analyses to test targeted use (e.g., specific ARDS endotypes or IL-6 inhibitor co-therapy).
OBJECTIVE: To inform treatment decisions in clinical practice, we conducted a meta-analysis to evaluate the efficacy and safety of imatinib in patients with COVID-19. METHODS: A comprehensive systematic search was conducted across multiple electronic databases to identify relevant randomized controlled trials (RCTs) comparing imatinib with placebo in patients with COVID-19. A meta-analysis was performed using Review Manager software version 5.3 and followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. RESULTS: The analysis included 4 studies with a total of 717 patients. The risk ratio (RR) for 28-day mortality in the imatinib group compared to the placebo group was 0.79 (95% confidence interval. CI 0.51-1.21; p = 0.28). There were no statistically significant differences in the duration of oxygen supplementation (MD = -0.13, 95% CI -2.57-2.31; p = 0.92) or the number of ventilator-free days (MD = 4.71, 95% CI -6.97-16.38; p = 0.43). Imatinib treatment did not significantly reduce the duration of hospital or intensive care unit (ICU) stay. Additionally, there was no significant difference between imatinib and placebo in the risk of any adverse events (AEs) or serious AEs. CONCLUSION: Imatinib did not significantly improve clinical outcomes in patients with COVID-19. Future research should consider subgroup analyses based on the biological heterogeneity of COVID-19-associated acute respiratory distress syndrome (ARDS) or the concurrent use of interleukin 6 (IL-6) receptor inhibitors to identify patient populations that may benefit from imatinib treatment.
2. Elevated KLF2 and YKL-40 with reduced vitamin A as predictive biomarkers for severity and prognosis in neonatal respiratory distress syndrome.
In a single-center retrospective cohort (128 NRDS vs 128 controls), KLF2 and YKL-40 were elevated while vitamin A was reduced in NRDS, with levels associated with severity and prognosis. Combining these biomarkers improved predictive accuracy for early identification and tailored management.
Impact: Proposes a pragmatic biomarker panel for NRDS severity and prognosis that could streamline early risk stratification in neonatal care.
Clinical Implications: These biomarkers could support early triage, monitoring intensity, and individualized interventions in NRDS once validated prospectively.
Key Findings
- KLF2 and YKL-40 levels were significantly higher in NRDS than controls, while vitamin A was lower.
- Biomarker levels correlated with NRDS severity and prognosis.
- Combining KLF2, YKL-40, and vitamin A improved predictive accuracy for clinical outcomes.
Methodological Strengths
- Case-control structure within a cohort with equal-sized healthy controls
- Standardized early sampling (within 1 hour) and validated assays (ELISA, HPLC)
Limitations
- Single-center retrospective design with potential confounding
- Incomplete reporting of long-term outcomes and external validation
Future Directions: Prospective, multicenter validation with predefined cut-offs and integration into risk scores; assessment of how biomarker-guided care affects outcomes.
OBJECTIVE: This study aimed to investigate the relationships between Krüppel-like factor 2 (KLF2), YKL-40, and vitamin A levels, as well as their association with the severity and prognosis of Neonatal Respiratory Distress Syndrome (NRDS), with the goal of improving predictive accuracy and clinical management. METHODS: A retrospective cohort study was conducted at Bozhou Municipal People's Hospital between January 2019 and January 2022. A total of 128 neonates diagnosed with NRDS were included, along with 128 healthy neonates as controls. Blood samples were collected within one hour of admission. Levels of KLF2, YKL-40, and vitamin A were measured using enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography (HPLC). Neonates were grouped based on NRDS severity, and the relationships between biomarker levels and clinical outcomes were analyzed. RESULTS: Significant differences in KLF2, YKL-40, and vitamin A levels were observed between the NRDS group and control group ( CONCLUSION: KLF2, YKL-40, and vitamin A are significant biomarkers for predicting the severity and prognosis of NRDS. Combining these biomarkers enhances predictive accuracy, aiding in the early identification and personalized management of neonates with NRDS.
3. Lung ultrasound score as a tool to assess pulmonary ventilation and disease severity in patients with acute respiratory distress syndrome.
In 35 ARDS patients, lung ultrasound scores correlated with oxygenation index, CT-derived lung density, and collapsed lung volume in moderate-to-severe ARDS but not mild ARDS. LUS may noninvasively reflect ventilation status and disease severity when CT access is limited.
Impact: Supports bedside ultrasound as an accessible modality to track ventilation and severity in moderate-to-severe ARDS, aligning LUS with CT-based metrics.
Clinical Implications: LUS scoring can aid monitoring and risk stratification in moderate-to-severe ARDS, potentially informing ventilator strategies when CT is impractical.
Key Findings
- Moderate-to-severe ARDS had higher lung density, LUS scores, and collapsed lung volume than mild ARDS (all P < 0.05).
- LUS scores moderately correlated with oxygenation index, lung density, and proportion of collapsed lung volume in moderate-to-severe ARDS.
- No significant correlations between LUS scores and these parameters were observed in mild ARDS.
Methodological Strengths
- Correlation with CT-derived metrics and arterial blood gases
- Use of Berlin definition to stratify ARDS severity
Limitations
- Small, single-center retrospective study (n=35)
- Cross-sectional assessment without longitudinal outcomes
Future Directions: Prospective multicenter studies to validate LUS thresholds, integrate into ventilator management algorithms, and assess outcome impact.
OBJECTIVE: To evaluate the effects of lung ultrasound (LUS) in assessing pulmonary ventilation status in patients with acute respiratory distress syndrome (ARDS). METHODS: A total of 35 ARDS patients aged 29-93 years, admitted to the Anesthesiology Intensive Care Unit and scheduled for chest computed tomography (CT), were retrospectively analyzed. Prior to the CT scan, arterial blood gas samples were collected, and LUS scores were obtained using a Sonostar portable ultrasound device. Based on the Berlin definition, patients were categorized into mild ARDS and moderate-to-severe ARDS groups. Lung density, lung volume, proportions of lung volume in different ventilation states, and LUS scores were compared between the groups. Spearman correlation analysis was used to evaluate the relationship between LUS scores and other parameters. RESULTS: Lung density, LUS scores, and the proportion of collapsed lung volume were significantly higher in the moderate-to-severe ARDS group than those in the mild ARDS group (all P < 0.05). In patients with moderate-to-severe ARDS, LUS scores showed a moderate correlation with the oxygenation index, lung density, and the proportion of collapsed lung volume. In mild ARDS patients, no significant correlation was observed between LUS scores and these parameters. CONCLUSION: LUS is an effective, non-invasive tool for evaluating pulmonary ventilation status in ARDS patients and is particularly reliable in assessing ventilation status in those with moderate-to-severe ARDS.